Greenwich LifeSciences, Inc. GLSI 深 滬
等待開盤 10-28 09:30:00 美东时间
17.42
+0.295
+1.72%
華盛通- 最 高17.58
- 今 開17.19
- 成交量 22.43万股
- 最 低 16.6588
- 昨 收 17.125
- 總市值 2.56亿
- 52周最高 34.10
- 市盈率 靜 --
- 換手率 1.53%
- 52周最低 7.78
- 委 比 -76.50%
- 總股本 1467.82万
- 歷史最高 158.07
- 量 比 2.31
- 振 幅 5.38%
- 歷史最低 3.262
- 每 手 1
- 風險率 6.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Di...
08-10 18:07
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Greenwich LifeSciences, a biopharmaceutical company, has extended the lock-up period for its directors, officers, and pre-IPO investors until January 31, 2027. During this time, these individuals cannot sell their shares unless the Board of Directors modifies the agreement. The company also plans to implement a leak-out plan for restricted sales after the lock-up period. CEO Snehal Patel highlighted the company's participation in BIO and BIO-Euro...
08-10 10:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
Greenwich LifeSciences announced regulatory approval to expand its Phase III FLAMINGO-01 clinical trial into the UK, potentially adding 5-10 new sites. The trial evaluates GLSI-100, an immunotherapy to prevent breast cancer recurrences. Collaborating with The Royal Marsden, a leading cancer research institute, the company aims to offer participation to UK patients. FLAMINGO-01 has shown a 70-80% reduction in recurrence rates in the non-HLA-A*02 a...
07-22 10:00
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
Greenwich LifeSciences provided updates on its Phase III FLAMINGO-01 trial evaluating GLSI-100 for preventing breast cancer recurrences. The DSMB recommended continuing the study as planned. Modifications include increasing enrollment to over 2,000 patients, combining HLA types, and using a commercial drug lot. Enrollment of non-HLA-A*02 patients has begun, potentially doubling the recruitment rate. Early data shows a 70-80% reduction in recurren...
07-20 10:00
Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of ...
07-16 19:31
Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical Trial
All European and US Sites to Treat Patients with Commercially Manufactured GP2 The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of GP...
07-09 18:04
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
Greenwich LifeSciences announced updates on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. All US and European sites are now using commercially manufactured GP2, with European approval following US clearance. The trial has expanded to approximately 170-180 sites globally. Over 1,300 patients have been screened, with the non-HLA-A*02 arm fully enrolled. Preliminary data shows ...
07-09 10:00
